Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 公司是一家主要致力于治疗消化性溃疡疾病药物、抗高血压药物等创新类药物的研发、生产、销售的高新技术企业。经过多年的发展，公司已成长为国内消化性溃疡疾病用药、抗高血压用药市场具有影响力的企业。2016 年度，公司生产的治疗消化性溃疡药物雷贝拉唑钠肠溶胶囊在雷贝拉唑钠制剂细分市场占有率为17.69%，排名第三位；2016 年度，公司生产的抗高血压药物厄贝沙坦胶囊在厄贝沙坦制剂细分市场占有率为9.50%，排名第四位。 公司致力于肠溶微丸和缓控释微丸制剂技术的研究，经过多年的发展，公司已成为国内领先的肠溶微丸和缓控释微丸制剂生产企业，缓控释微丸创新产业化基地于2013年3 月被广东省民营经济发展服务局、广东省中小企业局认定为“广东省中小企业创新产业示范基地”，缓控释微丸研究中心于2013 年12 月被广东省科学技术厅认定为“广东省缓控释微丸胶囊制剂工程技术研究中心”。公司微丸制剂主导产品雷贝拉唑钠肠溶胶囊为国家火炬计划项目产品、国家重点新产品，并被评为“广东省科学技术进步三等奖”。截至本招股意向书签署日，公司共有7 个微丸制剂产品，以雷贝拉唑钠肠溶胶囊为主，2014 年度、2015 年度、2016 年度，微丸制剂产品销售收入分别为25,676.95万元、28,997.98 万元、31,954.30 万元，年均复合增长率为11.56%。2017 年1-6 月，微丸制剂产品销售收入为16,731.55 万元，已达到2016 年全年的52.36%，保持持续快速增长。 公司是国家火炬计划重点高新技术企业、国家高新技术企业、广东省创新型企业，公司技术中心于2011 年1 月被广东省经济和信息化委员会、广东省财政厅等五部门认定为“广东省省级企业技术中心”，2015 年10 月被人力资源和社会保障部认定为“博士后科研工作站”，具有较强的技术创新能力和坚实的科研基础。截至本招股意向书签署日，公司共拥有53 个药品注册批件、10 个新药证书、4 个国家重点新产品、并拥有26 项专利，其中发明专利19项。
Main Business 化学药制剂、化学原料药、医药中间体的研发、生产和销售。
Legal Representative 刘杰
Top Executives
董事长：陈新民
董事：LIAO RAN,由春燕,刘杰
独立董事：王波,叶建木,TAN WEN
Top 5 Shareholder
Shareholder name Nature Holding Date
李希流通A股30.12%30/09/2024
陈新民限售股+流通A股30.12%30/09/2024
寇冰流通A股2.14%30/09/2024
上海甄投资产管理有限公司－甄投稳定8号私募证券投资基金流通A股1.13%30/09/2024
卢其慧流通A股1.09%30/09/2024
Company Secretary 苏军
Solicitors 广东广信君达律师事务所
Auditors 大华会计师事务所（特殊普通合伙）
Tel No 0756-7630378
Fax No 0756-7630035
Website www.rdpharma.cn
Email rd@rdpharma.cn
Company Address
Register: 广东省珠海市金湾区三灶镇机场北路6号
Office: 广东省珠海市金湾区三灶镇机场北路6号
Listing Date 05/01/2018
Shares Capital
Shares Capital: 334,893,286
Total A Share: 334,893,286
Listed A Share: 258,084,833
Non-tradable A Share: 76,808,453
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.200
DPS(RMB)* ¥ 0.200
NBV Per Share(RMB)* ¥ 3.521
Market Capitalization(RMB) 2.568B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.